Program
selonabant
Also written as “ANEB-001” and “V24343”.
Its studies are mostly in Obesity, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Anebulo Pharmaceuticals | 20 open or running | phase 2since Mar 8, 2022 | Mar 8, 2022 | none ahead |
| Vernalis (R&D) | 10 open or running | phase 1since Aug 6, 2008 | Aug 6, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2008First study: phase 1 study in ObesityNew to Vernalis (R&D)Vernalis (R&D) · NCT00734201 · 32 enrolled · United Kingdom
- Mar 8, 2022Anebulo Pharmaceuticals's first study: phase 2 study in Acute Cannabinoid IntoxicationNew to Anebulo PharmaceuticalsAnebulo Pharmaceuticals · NCT05282797 · 154 enrolled · Netherlands
- Sep 29, 2025Phase 1 study in Healthy VolunteersAnebulo Pharmaceuticals · NCT07211607 · 40 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07211607Healthy Volunteers · United States | 1 | Completed | Anebulo Pharmaceuticals | May 6, 2026 | 40 |
| NCT05282797Acute Cannabinoid Intoxication · Netherlands | 2 | Completed | Anebulo Pharmaceuticals | Aug 26, 2023 | 154 |
| NCT00734201Obesity · United Kingdom | 1 | Completed | Vernalis (R&D) | Mar 2009 | 32 |
How it is read
Names in the registry
- “selonabant”, 1 entry
- “ANEB-001”, 1 entry
- “V24343”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.